Blues’ TEC Delivers Mostly Negative Assessments For Three Technologies
This article was originally published in The Gray Sheet
Executive Summary
The Blue Cross Blue Shield Technology Evaluation Center considered balloon ostial dilation for the treatment for chronic rhinosinusitis; multianalyte testing for evaluation of adnexal masses; and nucleic acid sequencing-based testing of maternal plasma for fetal aneuploidy.
You may also be interested in...
News In Brief
Welch Allyn restructuring to cut jobs by 10% over three years. Neurovision v. NuVasive update. CMS opens coverage analysis on PET for solid tumors. More news briefs.
News In Brief
President issues business tax reform plan, patent battles heat up in fetal lab test space, and more news.
New Products In Brief
St. Jude Medical’s Genesis for chronic migraine